SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.

Rashmi ChughKarla V BallmanLee J HelmanShreyaskumar PatelJeremy S WhelanBrigitte WidemannYao LuDouglas S Hawkins Leo MascarenhasJohn W GlodJiuping JiYiping ZhangDenise Reinke Sandra J Strauss

Published in: Cancer (2020)

The combination of NIR and TMZ or IRN was tolerable, but at lower doses in comparison with conventional cytotoxic combinations. A triple-combination study of NIR, IRN, and TMZ has commenced.

Keyphrases

photodynamic therapy
drug release
fluorescent probe
open label
clinical trial
newly diagnosed
study protocol
structural basis
clinical evaluation